A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro

Pulmonary Pharmacology and Therapeutics

Volumn 23, Issue 4, 2010, Pages 283-291

  Sabatini, F ^a   Petecchia, L ^a   Boero, S ^a   Silvestri, M ^a   Klar, J ^b   Tenor, H ^b   Beume, R ^b   Hatzelmann, A ^b   Rossi, G A ^a  

^a G GASLINI INSTITUTE   (Italy)

^b Nycomed GmbH   (Germany)

Author keywords

Eotaxin; Extracellular matrix; Human lung fibroblasts; ICAM 1 expression; Myofibroblast transition; Roflumilast N oxide

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BASIC FIBROBLAST GROWTH FACTOR; CONNECTIVE TISSUE GROWTH FACTOR; DRUG METABOLITE; EOTAXIN; FIBRONECTIN; INTERLEUKIN 1BETA; MESSENGER RNA; PHOSPHODIESTERASE IV INHIBITOR; PROSTAGLANDIN E2; ROFLUMILAST; ROFLUMILAST N OXIDE; THYMIDINE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL FUNCTION; CELL STIMULATION; CELL STRAIN; COMPETITIVE INHIBITION; CONTROLLED STUDY; FETUS; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG FIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ACTINS; AMINOPYRIDINES; BENZAMIDES; CELLS, CULTURED; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; DRUG DELIVERY SYSTEMS; FIBROBLASTS; FIBRONECTINS; HUMANS; LUNG; MUSCLE, SMOOTH; PHOSPHODIESTERASE INHIBITORS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953088524     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.02.004     Document Type: Article

References (61)

1. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176 (2007) 532-555
2. Hogg J.C., Chu F., Utokaparch S., Woods R., Elliott W.M., Buzatu L., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350 (2004) 2645-2653
3. Curtis J.L., Freeman C.M., and Hogg J.C. The immunopathogenesis of chronic obstructive pulmonary disease: insights from recent research. Proc Am Thorac Soc 4 7 (2007 Oct 1) 512-521
4. Jeffery P.K. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 164 10 Pt 2 (2001 Nov 15) S28-S38
5. Giembycz M.A. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?. Br J Pharmacol 155 (2008) 288-290
6. Houslay M.D., Schafer P., and Zhang K.Y. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10 (2005) 1503-1519
7. Bender A.T., and Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58 (2006) 488-520
8. Spina D. PDE4 inhibitors: current status. Br J Pharmacol 155 (2008) 308-315
9. Boswell-Smith V., and Page C.P. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease. Expert Opin Investig Drugs 15 (2006) 1105-1113
10. Bundschuh D.S., Eltze M., Barsig J., Wollin L., Hatzelmann A., and Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 297 (2001) 280-290
11. Hatzelmann A., and Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297 (2001) 267-279
12. Sanz M.J., Cortijo J., Taha M.A., Cerdá-Nicolás M., Schatton E., Burgbacher B., et al. Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol 152 (2007) 481-492
13. Grootendorst D.C., Gauw S.A., Verhoosel R.M., Sterk P.J., Hospers J.J., Bredenbroker D., et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62 (2007) 1081-1087
14. Martorana P.A., Beume R., Lucattelli M., Wollin L., and Lungarella G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 172 (2005) 848-853
15. Hohlfeld J.M., Schoenfeld K., Lavae-Mokhtari M., Schaumann F., Mueller M., Bredenbroeker D., et al. Roflumilast attenuates pulmonary inflammation upon segmental allergen challenge in healthy subjects: a randomized, placebo-controlled trial. Pulm Pharmacol Ther 21 (2008) 616-623
16. Izikki M., Raffestin B., Klar J., Hatzelmann A., Marx D., Tenor H., et al. Effects of roflumilast, a phosphodiesterase-4 inhibitor on hypoxia- and monocrotaline-induced pulmonary hypertension in rats. J Pharmacol Exp Ther 330 (2009) 54-62
17. Kumar R.K., Herbert C., Thomas P.S., Wollin L., Beume R., Yang M., et al. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther 307 (2003) 349-355
18. Cortijo J., Iranzo A., Milara X., Mata M., Cerdá-Nicolás M., Ruiz-Sauri A., et al. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol 156 (2009) 534-544
19. 2 inhibition of TGF-ß1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol 296 (2009) L959-L969
20. Bethke T.D., Böhmer G.M., Hermann R., Hauns B., Fux R., Mörike K., et al. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 47 (2007) 26-36
21. Boero S., Sabatini F., Silvestri M., Petecchia L., Nachira A., Pezzolo A., et al. Modulation of human lung fibroblast functions by ciclesonide: evidence for its conversion into the active metabolite desisobutyryl-ciclesonide. Immunol Lett 112 (2007) 39-46
22. Sabatini F., Silvestri M., Sale R., Serpero L., Giuliani M., Scarso L., et al. Concentration-dependent effects of mometasone furoate and dexamethasone on foetal lung fibroblast functions involved in airway inflammation and remodelling. Pulm Pharmacol Ther 16 (2003) 287-297
23. Peter D., Jin S.L., Conti M., Hatzelmann A., and Zitt C. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol 178 (2007) 4820-4831
24. Thompson W.J., and Appleman M.M. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cycl Nucl Res 10 (1979) 69-92
25. Bauer A.C., and Schwabe U. An improved assay of cyclic 3′5′-nucleotide phosphodiesterase with QAE sephadex A-25. Naunyn Schmiedebergs Arch Pharmacol 311 (1980) 193-198
26. Dunkern T.R., Feurstein D., Rossi G.A., Sabatini F., and Hatzelmann A. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. Eur J Pharmacol 572 (2007) 12-22
27. Martin-Chouly C.A.E., Astier A., Jacob C., Pruniaux M.P., Bertrand C., and Lagente V. Modulation of matrix metalloprotease production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. Life Sci 75 (2004) 823-840
28. Racké K., Haag S., Bahulayan A., and Warnken M. Pulmonary fibroblasts, an emerging target for anti-obstructive drugs. Naunyn Schmiedebergs Arch Pharmacol 378 (2008) 193-201
29. Silvestri M., Fregonese L., Sabatini F., Dasic G., and Rossi G.A. Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression. Eur Respir J 18 (2001) 139-145
30. Noguchi K., Iwasaki K., Shitashige M., and Ishikawa I. Prostaglandin E2 receptors of the EP2 and EP4 subtypes downregulate tumor necrosis factor α-induced intercellular adhesion moclecule-1 expression in human gingival fibroblasts. J Periodont Res 34 (1999) 478-485
31. Iwasaki K., Noguchi K., and Ishikawa I. Prostaglandin E2 and I2 regulate intercellular adhesion molecule-1 expression in interleukin-1ß-stimulated human gingival fibroblasts. J Periodont Res 34 (1999) 97-104
32. Rahman A., Anwar K.N., Minhajuddin M., Bijli K.M., Javaid K., True A.L., et al. cAMP targeting of p38 MAP kinase inhibits thrombin-induced NF-kappaB activation and ICAM-1 expression in endothelial cells. Am J Physiol Lung Cell Mol Physiol 287 (2004) L1017-L1024
33. Burns A.R., Smith C.W., and Walker D.C. Unique structural features that influence neutrophil emigration into the lung. Physiol Rev 83 (2003) 309-336
34. Wollin L., Barsig J., Marx D., Wohlsen A., and Beume R. Inhibition by roflumilast versus cilomilast of pulmonary leukocyte accumulation and TNF-α-release in a rat model of LPS-induced pulmonary neutrophilia. Eur Respir J 22 (2003) 107s
35. Martorana P.A., Lunghi B., Lucatelli M., De Cunto G., Beume R., and Lungarello G. Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice. BMC Pulm Med 8 (2009) 17
36. Leclerc O., Lagente V., Planquois J.M., Berthelier C., Artola M., Eichholtz T., et al. Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice. Eur Respir J 27 (2006) 1102-1109
37. Weidenbach A., Braun C., Schwoebel F., Beume R., and Marx D. Therapeutic effect of various PDE4 inhibitors on cigarette smoke-induced pulmonary neutrophilia in mice. Am J Respir Crit Care Med 177 Suppl. A652 (2008) [abstract]
38. Bocchino V., Bertorelli G., Bertrand C.P., Ponath P.D., Newman W., Franco C., et al. Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Allergy 57 (2002) 17-22
39. Puxeddu I., Bader R., Piliponsky A.M., Reich R., Levi-Schaffer F., and Berkman N. The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts. J Allergy Clin Immunol 117 (2006) 103-110
40. Huaux F., Gharaee-Kermani M., Liu T., Morel V., McGarry B., Ullenbruch M., et al. Role of eotaxin-1 (CCL-11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. Am J Pathol 167 (2005) 1485-1496
41. Pang L., and Knox A.J. Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta2-agonists and corticosteroids. FASEB J 15 (2001) 261-269
42. Hallsworth M.P., Twort C.H., Lee T.H., and Hirst S.J. beta(2)-adrenoceptor agonists inhibit release of eosinophil-activating cytokines from human airway smooth muscle cells. Br J Pharmacol 132 (2001) 729-741
43. Wuyts W.A., Vanaudenaerde B.M., Dupont L.J., Demedts M.G., and Verleden G.M. Modulation by cAMP of IL-1ß-induced eotaxin and MCP-1 expression and release in human airway smooth muscle cells. Eur Respir J 22 (2003) 220-226
44. Clark J.G., Kostal K.M., and Marino B. Bleomycin-induced pulmonary fibrosis in hamsters. J Clin Invest 72 (1983) 2082-2091
45. Huang S.K., Wettlaufer S.H., Chung J., and Peters-Golden M. Prostaglandin E2 inhibits specific lung fibroblast functions via selective actions of PKA and Epac-1. Am J Respir Cell Mol Biol 39 (2008) 482-489
46. Haag S., Warnken M., Juergens U.R., and Racké K. Role of Epac1 in mediating anti-proliferative effects of prostanoid EP(2) receptors and cAMP in human lung fibroblasts. Naunyn Schmiedebergs Arch Pharmacol 378 (2008) 617-630
47. Elias J.A., Gustilo K., Baeder W., and Freundlich B. Synergistic stimulation of fibroblast prostaglandin production by recombinant interleukin 1 and tumor necrosis factor. J Immunol 138 (1987) 3812-3816
48. Kohyama T., Liu X., Wen F.Q., Kobayashi T., Fang Q., Abe S., et al. Cytokines modulate cilomilast response in lung fibroblasts. Clin Immunol 111 (2004) 297-302
49. 2 mediates IL-1ß-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors. J Immunol 180 (2008) 637-646
50. McAnulty R.J., Hernandez-Rodriguez N.A., Mutsaers S.E., Coker R.K., and Laurent G.J. Indomethacin suppresses the anti-proliferative effects of transforming growth factor-ß isoforms on fibroblast cell cultures. Biochem J 321 (1997) 639-643
51. Liu X., Ostrom R., and Insel P. cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. Am J Physiol Cell Physiol 286 (2004) C1089-C1099
52. Chung K.F. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 18 (2001) 50s-59s
53. Klein T., Shephard P., Kleinert H., and Kömhoff M. Regulation of cyclooxygenase-2 expression by cyclic AMP. Biochim Biophys Acta 1773 (2007) 1605-1618
54. Kolodsick J.E., Peters-Golden M., Larios J., Toews G.B., Thannickal V.J., and Moore B.B. Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E-prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 29 (2003) 537-544
55. Black S.A., Palamakumbura A.H., Stan M., and Trackman P.C. Tissue-specific mechanisms for CCN2/CTGF persistence in fibrotic gingiva. J Biol Chem 282 (2007) 15416-15429
56. Burgess J.K., Oliver B.G.G., Poniris M.H., Ge Q., Boustany S., Cox N., et al. A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro. J Allergy Clin Immunol 118 (2006) 649-657
57. 3H] thymidine incorporation in human bronchial smooth muscle cells. Eur Respir J 26 Suppl. 49 (2005) 717s [abstract]
58. Kohyama T., Liu X., Wen F.Q., Zhu Y.K., Wang H., Kim H.J., et al. PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 26 (2002) 694-701
59. Tenor H., Hedbom E., Häuselmann H.J., Schudt C., and Hatzelmann A. Phosphodiesterase isoenzyme families in human osteoarthritis chondrocytes - functional importance of phosphodiesterase 4. Br J Pharmacol 135 (2002) 609-618
60. Oger S., Méhats C., Dallot E., Ferré F., and Leroy M.J. Interleukin-1ß induces phosphodiesterase 4B2 expression in human myometrial cells through a prostaglandin E2- and cyclic adenosine 3′,5′-monophosphate-dependent pathway. J Clin Endocrinol Metab 87 (2002) 5524-5531
61. Klar J., Sabatini F., Schatton E., Burgbacher B., Rossi G.A., Hatzelmann A., et al. Roflumilast N-oxide reduces human fibroblast function. Eur Respir J 30 Suppl. (2007) 544s [abstract]